Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) by osimertinib and continued treatment with dose reduction for postoperative recurrence of lung adenocarcinoma: a case report.

ABSTRACT:

Background

Osimertinib is the standard third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) of choice for EGFR mutation-positive non-small cell lung cancer. Its major adverse effects include diarrhea and skin symptoms, although syndrome of inappropriate secretion of antidiuretic hormone (SIADH) has been reported as a rare event. In previous reports, patients were switched to another drug after the onset of SIADH. We report the first case of osimertinib-induced SIADH in a patient with lung adenocarcinoma with an EGFR T790M mutation, with, therefore, no effective therapeutic alternative, where the patient was able to resume treatment at a reduced dose without recurrence of SIADH.

Case description

An 80-year-old man with a history

SUBMITTER: Nishii M 

PROVIDER: S-EPMC12541871 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature